Literature DB >> 22521544

Characterization of sphere-forming cells with stem-like properties from the small cell lung cancer cell line H446.

Xiaofei Qiu1, Zhengyan Wang, Yanlei Li, Yajing Miao, Yu Ren, Yajing Luan.   

Abstract

A relatively novel paradigm in tumor biology hypothesizes that cancer growth is driven by tumor cells with stem-like properties. However, direct proof of a population of stem cells in small cell lung cancer (SCLC) remains elusive. In this study, we enriched for stem-like cells from the SCLC cell line H446 by growing them as spheres in a defined serum-free medium. Sphere-derived cells have increased in vitro clonogenic and in vivo tumorigenic potentials as well as drug-resistant properties. After enrichment for stem-like cells, we used multiple candidate stem cell markers to examine the expression profile and found that the sphere-derived cells contained a higher proportion of cells expressing the stem cell surface markers uPAR and CD133 when compared with parental cells. To identify a selectable marker for the sphere-forming cells, we evaluated the sphere-forming abilities of uPAR(+) and uPAR(-) cells as well as the sphere-forming abilities of CD133(+) and CD133(-) cells. Both CD133(+) and CD133(-) cell fractions were capable of forming spheres, and no statistically significant difference was observed in the sphere-forming efficiency between these two populations. In contrast, cells derived from the uPAR(+) fraction were capable of forming spheres, whereas cells derived from the uPAR(-) fraction remained as single cells. Moreover, uPAR(+) cells efficiently formed transplantable tumors, whereas uPAR(-) cells were unable to initiate tumors when transplanted at equivalent cell numbers. In addition, uPAR(+) cells could differentiate into CD56(+)cells, CK(+) cells, and uPAR(-) cells. These data support the existence of a population of tumor sphere-forming cells with stem cell properties in the H446 SCLC cell line. Furthermore, the stem cell population may be enriched in cells expressing the uPAR cell surface marker.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22521544     DOI: 10.1016/j.canlet.2012.04.004

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  44 in total

Review 1.  Cancer stem cells: progress and challenges in lung cancer.

Authors:  Amanda K Templeton; Shinya Miyamoto; Anish Babu; Anupama Munshi; Rajagopal Ramesh
Journal:  Stem Cell Investig       Date:  2014-04-15

2.  Differential effects of mesenchymal stem cells on a heterogeneous cell population within lung cancer cell lines.

Authors:  Dan Luo; Xiuping Yan; Dengqun Liu; Xiangdong Zhou; Guoxiang Liu
Journal:  Mol Cell Biochem       Date:  2013-03-03       Impact factor: 3.396

3.  Co-expression of uPAR and CXCR4 promotes tumor growth and metastasis in small cell lung cancer.

Authors:  Yanlei Li; Yao Shen; Yajing Miao; Yajing Luan; Baocun Sun; Xiaofei Qiu
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

Review 4.  Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Cancers (Basel)       Date:  2018-07-27       Impact factor: 6.639

5.  HMGA2 regulates CD44 expression to promote gastric cancer cell motility and sphere formation.

Authors:  Junying Sun; Baocun Sun; Dongwang Zhu; Xiulan Zhao; Yanhui Zhang; Xueyi Dong; Na Che; Jing Li; Fang Liu; Nan Zhao; Danfang Zhang; Tieju Liu; Xian Lin
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

6.  Upregulation of histone-lysine methyltransferases plays a causal role in hexavalent chromium-induced cancer stem cell-like property and cell transformation.

Authors:  Zhishan Wang; Jianjun Wu; Brock Humphries; Kazuya Kondo; Yiguo Jiang; Xianglin Shi; Chengfeng Yang
Journal:  Toxicol Appl Pharmacol       Date:  2018-01-31       Impact factor: 4.219

7.  Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma.

Authors:  Xinwei Yun; Keqiang Zhang; Jinhui Wang; Rajendra P Pangeni; Lu Yang; Melissa Bonner; Jun Wu; Jami Wang; Isaac K Nardi; Ming Gao; Dan J Raz
Journal:  Mol Cancer Res       Date:  2018-05-02       Impact factor: 5.852

8.  Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.

Authors:  Bruna Corominas-Faja; Cristina Oliveras-Ferraros; Elisabet Cuyàs; Antonio Segura-Carretero; Jorge Joven; Begoña Martin-Castillo; Enrique Barrajón-Catalán; Vicente Micol; Joaquim Bosch-Barrera; Javier A Menendez
Journal:  Cell Cycle       Date:  2013-09-17       Impact factor: 4.534

Review 9.  Cancer stem cells in lung cancer: Evidence and controversies.

Authors:  Muhammad Alamgeer; Craig D Peacock; William Matsui; Vinod Ganju; D Neil Watkins
Journal:  Respirology       Date:  2013-07       Impact factor: 6.424

Review 10.  Cancer stem cells in small cell lung cancer.

Authors:  Jordi Codony-Servat; Alberto Verlicchi; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2016-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.